Previous 10 | Next 10 |
Unity Biotechnology (NASDAQ: UBX ) has announced results from its first-in-human Phase 1 study of UBX0101 in patients with moderate to severe osteoarthritis (OA) of the knee. More news on: Unity Biotechnology, Inc., Healthcare stocks news, Read more ...
Clinical results support senescent cell elimination with UBX0101 as a potential treatment for osteoarthritis Topline results demonstrate a dose-dependent and clinically meaningful impact on pain Call with management scheduled for today at 8:00 a.m. EDT SAN FRANCISCO, June 18,...
The following healthcare companies have recently filed for mixed shelf offerings: More news on: Unity Biotechnology, Inc., Kiniksa Pharmaceuticals, Ltd., Evelo Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...
UNITY Biotechnology (NASDAQ: UBX ) inks an agreement with the University of San Francisco (UCSF) for exclusive global rights to alpha-Klotho protein, a circulating factor associated with improved cognitive performance. According to UCSF researchers, the protein was identified as an "aging-...
SAN FRANCISCO, May 29, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, and UC San Francisco (UCSF) today announced that UNIT...
SAN FRANCISCO, May 23, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team...
Unity Biotechnology (NASDAQ: UBX ): Q1 GAAP EPS of -$0.44. More news on: Unity Biotechnology, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN FRANCISCO, April 29, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report results for the second quarter ended Mar...
Chiasma (NASDAQ: CHMA ) initiated with Overweight rating and $18 (208% upside) price target. Shares up 3% premarket. More news on: Chiasma, Mylan Inc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Stocks on the move, Read more ...
Unity Biotechnology (NASDAQ: UBX ): Q4 GAAP EPS of -$0.53 misses by $0.10. More news on: Unity Biotechnology, Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Unity Biotechnology Inc. Company Name:
UBX Stock Symbol:
NASDAQ Market:
Unity Biotechnology Inc. Website:
SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this n...
SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2024. "Our team r...
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at t...